IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on July 1, 2008
(Investigative Ophthalmology and Visual Science. )
© 2008 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.08-1689

This Article
Right arrow Full Text (P<P[PDF])
Right arrow All Versions of this Article:
iovs.08-1689v1
49/7/3115    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keane, P. A
Right arrow Articles by Sadda, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keane, P. A
Right arrow Articles by Sadda, S. R.

Article

Quantitative Subanalysis of Optical Coherence Tomography after treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration

Pearse A Keane 1, Sandra Liakopoulos 2, Sharel C Ongchin 1, Florian M Heussen 1, Sandeep Msutta 1, Karen T Chang 1, Alexander C Walsh 1, and SriniVas R. Sadda 1*

1 Ophthalmology, Doheny Retina Institute, Los Angeles, California, United States
2 Ophthalmology, University of Cologne, Cologne, Germany

* To whom correspondence should be addressed. E-mail: sadda{at}usc.edu.


   Abstract

Purpose: To investigate the effects of ranibizumab on retinal morphology in patients with neovascular age-related macular degeneration (AMD) using optical coherence tomography (OCT) quantitative subanalysis. Methods: Data from 95 patients receiving intravitreal ranibizumab for neovascular AMD were collected. StratusOCT images were analyzed using custom software entitled "OCTOR" which allows precise positioning of pre-specified boundaries on every B-scan. Changes in thickness/volume of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pigment epithelial detachments (PEDs) at week 1, and at months 1, 3, 6 and 9 post-treatment were calculated. Results: Total retinal volume reached its nadir at month 1, with an average reduction of 0.43 mm3 (P<0.001). By month 9, this initial change had been reduced to 0.32 mm3 (P=0.0011). Total SRF volume reached its lowest level by month 1, with an average reduction of 0.24 mm3 (P<0.001). This reduction lessened subsequently, to 0.18 mm3 by month 9. There was an average 0.3 mm3 decrease in total PED volume by month 1 (P<0.001), and this later declined further, to 0.45 mm3 by month 9 (P=0.0014). Total SRT volume was reduced by an average of 0.07 mm3 at month 1 (P=0.0159) and subsequently remained constant. Conclusions: Although neurosensory retinal edema and SRF, showed an early reduction to nadir following initiation of ranibizumab therapy, the effect on the retina was attenuated over time, suggesting a possible tachyphylaxis. PED volume showed a slower but progressive reduction. Manual quantitative OCT subanalysis may allow a more precise understanding of anatomic outcomes and their correlation with visual acuity.

Key Words: age-related macular degeneration, optical coherence tomography, angiogenesis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Association for Research in Vision and Ophthalmology